Cargando…
The Impact of Sarcopenia in Patients with Peritoneal Surface Disease
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is increasingly performed in patients with advanced cancer in the abdomen. This treatment prolongs survival for some patients but is known to have a substantial rate of complications. Choosing patients for this procedure can be diff...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435582/ https://www.ncbi.nlm.nih.gov/pubmed/34526857 http://dx.doi.org/10.3389/pore.2021.638857 |
_version_ | 1783751823524364288 |
---|---|
author | Juris, Aubrey Taylor-Gehman, Amanda Spencer, Brianna Schaefer, Eric Pameijer, Colette |
author_facet | Juris, Aubrey Taylor-Gehman, Amanda Spencer, Brianna Schaefer, Eric Pameijer, Colette |
author_sort | Juris, Aubrey |
collection | PubMed |
description | Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is increasingly performed in patients with advanced cancer in the abdomen. This treatment prolongs survival for some patients but is known to have a substantial rate of complications. Choosing patients for this procedure can be difficult, and no clear guidelines exist. Muscle mass is a general measure of a patient’s wellness, meaning that patients with low muscle mass for their body weight tend to have more complications from treatment and overall do worse. We evaluated muscle mass prior to surgery in our Cytoreductive surgery/hyperthermic intraperitoneal chemotherapy population to assess how many patients have low muscle mass and the impact on outcomes, such as length of hospital stay, complications and survival. We find that about 25% of our patient population has low muscle mass, and low muscle mass is associated with a higher burden of cancer and shorter survival. We were able to evaluate muscle mass in a small number of patients after surgery, expecting to find decreased muscle mass in all the patients after a complex operation and long recovery. In fact, none of the patients had low muscle mass, including those who were low prior to surgery. |
format | Online Article Text |
id | pubmed-8435582 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84355822021-09-14 The Impact of Sarcopenia in Patients with Peritoneal Surface Disease Juris, Aubrey Taylor-Gehman, Amanda Spencer, Brianna Schaefer, Eric Pameijer, Colette Pathol Oncol Res Society Journal Archive Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is increasingly performed in patients with advanced cancer in the abdomen. This treatment prolongs survival for some patients but is known to have a substantial rate of complications. Choosing patients for this procedure can be difficult, and no clear guidelines exist. Muscle mass is a general measure of a patient’s wellness, meaning that patients with low muscle mass for their body weight tend to have more complications from treatment and overall do worse. We evaluated muscle mass prior to surgery in our Cytoreductive surgery/hyperthermic intraperitoneal chemotherapy population to assess how many patients have low muscle mass and the impact on outcomes, such as length of hospital stay, complications and survival. We find that about 25% of our patient population has low muscle mass, and low muscle mass is associated with a higher burden of cancer and shorter survival. We were able to evaluate muscle mass in a small number of patients after surgery, expecting to find decreased muscle mass in all the patients after a complex operation and long recovery. In fact, none of the patients had low muscle mass, including those who were low prior to surgery. Frontiers Media S.A. 2021-08-30 /pmc/articles/PMC8435582/ /pubmed/34526857 http://dx.doi.org/10.3389/pore.2021.638857 Text en Copyright © 2021 Juris, Taylor-Gehman, Spencer, Schaefer and Pameijer. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Society Journal Archive Juris, Aubrey Taylor-Gehman, Amanda Spencer, Brianna Schaefer, Eric Pameijer, Colette The Impact of Sarcopenia in Patients with Peritoneal Surface Disease |
title | The Impact of Sarcopenia in Patients with Peritoneal Surface Disease |
title_full | The Impact of Sarcopenia in Patients with Peritoneal Surface Disease |
title_fullStr | The Impact of Sarcopenia in Patients with Peritoneal Surface Disease |
title_full_unstemmed | The Impact of Sarcopenia in Patients with Peritoneal Surface Disease |
title_short | The Impact of Sarcopenia in Patients with Peritoneal Surface Disease |
title_sort | impact of sarcopenia in patients with peritoneal surface disease |
topic | Society Journal Archive |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435582/ https://www.ncbi.nlm.nih.gov/pubmed/34526857 http://dx.doi.org/10.3389/pore.2021.638857 |
work_keys_str_mv | AT jurisaubrey theimpactofsarcopeniainpatientswithperitonealsurfacedisease AT taylorgehmanamanda theimpactofsarcopeniainpatientswithperitonealsurfacedisease AT spencerbrianna theimpactofsarcopeniainpatientswithperitonealsurfacedisease AT schaefereric theimpactofsarcopeniainpatientswithperitonealsurfacedisease AT pameijercolette theimpactofsarcopeniainpatientswithperitonealsurfacedisease AT jurisaubrey impactofsarcopeniainpatientswithperitonealsurfacedisease AT taylorgehmanamanda impactofsarcopeniainpatientswithperitonealsurfacedisease AT spencerbrianna impactofsarcopeniainpatientswithperitonealsurfacedisease AT schaefereric impactofsarcopeniainpatientswithperitonealsurfacedisease AT pameijercolette impactofsarcopeniainpatientswithperitonealsurfacedisease |